Lyell Immunopharma (LYEL) Event Aug. 04, 2022, 00:00 UTC (42% Neutral) Lyell Immunopharma, Inc. (LYEL) Reports Profit for 2022-06-30 Full text
Register to leave comments News bot Oct. 29, 2025, 11:59 a.m. 🏢 Lyell Immunopharma (LYEL) - Form 10-Q Quarterly Report Quarterly financial filing submitted to the SEC 📋 Filing Information 📄 Form Type: 10-Q 📅 Filing Date: 2022-08-04 📊 Period of Report: 2022-06-30 ⏰ Accepted: N/A 📊 Key Financial Metrics (Period-over-Period Comparison) Metric Current Period Previous Period Change ($) Change (%) Trend Net Income/Loss $35.30M $35.30M N/A +0.00% ➡️ Total Assets $1.13B $1.02B $105.73M +10.35% 📈 Total Liabilities $197.62M $153.63M $43.99M +28.63% 📉 Stockholders' Equity $1.02B $-451.78M $1.47B +326.21% 📈 Operating Income/Loss $-118.08M $-105.84M $-12.24M -11.56% 📈 R&D Expense $100.00K $1.50M $-1.40M -93.33% 📈 Revenues $35.30M $35.30M N/A +0.00% ➡️ Earningspersharebasic $0.14 $0.14 N/A +0.00% ➡️ Earningspersharediluted $0.14 $0.14 N/A +0.00% ➡️ 📈 Financial Trend Analysis ✅ Maintained profitability • ⚖️ Liability growth outpaced asset growth 📎 View Full 10-Q Filing on SEC.gov Access the complete official filing document
🏢 Lyell Immunopharma (LYEL) - Form 10-Q Quarterly Report
📋 Filing Information
Key Financial Metrics (Period-over-Period Comparison)
Financial Trend Analysis
✅ Maintained profitability • ⚖️ Liability growth outpaced asset growth
📎 View Full 10-Q Filing on SEC.gov
Access the complete official filing document